[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360654-105":59,"doc-detail-360654-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-germline-profiling-of-high-grade-serous-ovarian-cancer-using-whole-exome-sequencing","Comprehensive Germline Profiling of High-Grade Serous Ovarian Cancer Using Whole-Exome Sequencing","","Ovarian cancer screening is not recommended for the general population, so attention has shifted to women with elevated hereditary risk. Germline BRCA1/2 pathogenic variants account for a substantial portion of inherited risk, yet known germline variants do not fully explain familial ovarian cancer burden. Whole-exome sequencing of blood from 231 individuals (39 HGSOC, 192 controls stratified by family history) assessed P/LP germline variants and their links to family cancer history. Somatic comparisons using 1:4 propensity matching and CHIP-related variants were also performed. P/LP germline variants were found in 56.4% of HGSOC, 49.4% of FH-positive controls, and 33.3% without FH, showing shared mutation patterns. CHIP mutations appeared in 6.3% of HGSOC and 8.5% of controls. Results indicate genomic overlap, supporting consideration of germline screening for earlier diagnosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-germline-profiling-of-high-grade-serous-ovarian-cancer-using-whole-exome-sequencing/360654/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-germline-profiling-of-high-grade-serous-ovarian-cancer-using-whole-exome-sequencing/360654.png","ImageObject",300,407,{"name":92,"@type":93},"Jasmine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is ovarian cancer screening focused on women with elevated hereditary risk?","Question",{"text":112,"@type":113},"Routine screening is not recommended for the general population due to limited effectiveness, so screening efforts emphasize individuals with increased hereditary risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was whole-exome sequencing used in this study?",{"text":117,"@type":113},"Whole-exome sequencing was performed on blood samples from 231 individuals to identify pathogenic or likely pathogenic germline variants in cancer-related genes and evaluate associations with family cancer history.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about germline variants in HGSOC patients versus controls?",{"text":121,"@type":113},"P/LP germline variants were detected in 56.4% of HGSOC patients, 49.4% of controls with family history, and 33.3% of controls without family history, with similar mutation patterns in ovarian cancer-related genes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360654,1790188764,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Article  \nComprehensive Germline Profiling of High-Grade Serous Ovarian Cancer Using Whole-Exome Sequencing  \nHye-Lim Cho 1,†, Seong Eun Bak 2,†, Mi-Ryung Han 1,3,* and Youn Jin Choi 4,5, *  \nAcademic Editors: Stefania  \nScicchitano and Cinzia Garofalo Received: 27 March 2026  \nRevised: 12 June 2026  \nAccepted: 17 June 2026  \nPublished: 19 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon 22014, Republic of Korea; [joao216@inu.ac.kr](joao216@inu.ac.kr)  \n2 Department of Obstetrics and Gynecology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea; [newsseong@gmail.com](newsseong@gmail.com)  \n3 Institute for New Drug Development, College of Life Science and Bioengineering, Incheon National University, Incheon 22014, Republic of Korea  \n4 Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea  \n5 Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea  \n* Correspondence: [genetic0309@inu.ac.kr](genetic0309@inu.ac.kr) (M.-R.H.); [yunno@catholic.ac.kr](yunno@catholic.ac.kr) (Y.J.C.)† These authors contributed equally to this work.  \nAbstract  \nWhile ovarian cancer screening isnot recommended in the general population, attention has shifted to screening women with elevated hereditary risks. Although germline BRCA 1/2 pathogenic variants account for 40% of inherited ovarian cancer risk and family history (FH) remains important, known germline variants alone do not fully explain familial ovarian cancer risk. Whole-exome sequencing (WES) was performed on blood samples taken from 231 individuals, including 39 patients with high-grade serous ovarian cancer (HGSOC) and 192 healthy controls (HCs) stratified by FH. We analyzed pathogenic or likely pathogenic (P/LP) germline variants in cancer-related genes and assessed their association with family cancer history. Additionally, we performed somatic variant comparisons using 1:4 propensity score matching and analyzed clonal hematopoiesis of indeterminate potential (CHIP)-related somatic variants. P/LP germline variants were detected in 56.4% of HGSOC patients, 49.4% of controls with FH, and 33.3% without. The HGSOC group and controls with FH exhibited similar P/LP germline mutation patterns in ovarian cancerrelated genes. From CHIP analysis, somatic CHIP mutations were detected in 6.3% of the HGSOC group and 8.5% in HCs. Our findings demonstrate genomic overlap between ovarian cancer patients and FH-positive individuals. Therefore, germline variant screening could be considered to facilitate early diagnosis.  \nKeywords: germline variants; somatic variants; high-grade serous ovarian cancer; hereditary breast and ovarian cancer; family history; screening; whole-exome sequencing; clonal hematopoiesis; propensity score matching  \n1. Introduction  \nGlobally, ovarian cancer is the third most common gynecological malignancy and the second leading cause of death in this category [1] . Due to early detection challenges, approximately 80% of cases are diagnosed at stages III or IV, resulting in a 5-year survival rate of less than 45%[2] . Large-scale ovarian cancer screening studies in the United Kingdom (UK)  \n(e.g., the UK Collaborated Trial of Ovarian Cancer Screening trial) have examined transvaginal sonography and tumor markers (e.g., CA125) in the general population to enhance survival outcomes. This long-term follow-up study reported limited effectiveness and concluded that routine screening was not warranted in the general population [3] . Thus, screening efforts have shifted toward women with elevated ","cbCaimQADG4Xe8nQ","https://ap.wps.com/l/cbCaimQADG4Xe8nQ","pdf",1323512,14,"English","# Introduction\n## Hereditary risk and screening shift\n## Germline variant limitations\n## Multi-gene panel testing and risk stratification","[{\"question\":\"Why is ovarian cancer screening focused on women with elevated hereditary risk?\",\"answer\":\"Routine screening is not recommended for the general population due to limited effectiveness, so screening efforts emphasize individuals with increased hereditary risk.\"},{\"question\":\"How was whole-exome sequencing used in this study?\",\"answer\":\"Whole-exome sequencing was performed on blood samples from 231 individuals to identify pathogenic or likely pathogenic germline variants in cancer-related genes and evaluate associations with family cancer history.\"},{\"question\":\"What did the study find about germline variants in HGSOC patients versus controls?\",\"answer\":\"P/LP germline variants were detected in 56.4% of HGSOC patients, 49.4% of controls with family history, and 33.3% of controls without family history, with similar mutation patterns in ovarian cancer-related genes.\"}]","Comprehensive Germline Profiling of High-Grade Serous Ovarian Cancer Using Whole-Exome Sequencing | PDF",1790140857,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b656d574b9da5097d4e997505f3e3de4.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3e47fabf51ea1112f0d8d5ae4b5a041.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdfb0c2f11be643b5b52d96b392964ff.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f80942f9544181030fd4d2887ac0d8b.webp",980,1385]